The deal will allow Cubist to obtain Entereg, an oral, peripherally acting mu opioid receptor antagonist. The drug is the only FDA-approved treatment for speeding upper and lower gastrointestinal recovery time following partial large or small bowel resection surgery with primary anastomosis.
Related Articles on Pain Management:
Adaptation to Upright Walking Leaves Humans Susceptible to Backbone Fractures, Pain
Researchers to Study ‘Scrambler Therapy’ for Pain Relief
Chronic Pain Care for Women Cost $12.9 Billion in 2008
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
